GENETIC TECHNOLOGIES LIMITED — Capital/Financing Update 2008

Jan 14, 2008

==> picture [562 x 68] intentionally omitted <==

==> picture [562 x 69] intentionally omitted <==

ASX ANNOUNCEMENT January 15[th] , 2008

Licensing Program Update

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) wishes to advise of its progress in licensing its core intellectual property pertaining to non-coding DNA.

During the 2007 financial year, GTG earned $11.3 million in license fees which was significantly higher than in previous years. So far this financial year, the Company has continued to make good progress with approximately $6.6 million in license fees having been received to the end of December 2007. Several new licenses, including those previously announced, as well as licenses recently granted to Kimball Genetics and Prometheus Laboratories have helped GTG to generate a solid first half result.

While predicting the timing and quantum of future license fees is inherently difficult, the Company remains satisfied with the progress of its licensing program.

FOR FURTHER INFORMATION PLEASE CONTACT

Michael B. Ohanessian Chief Executive Officer

Genetic Technologies Limited (ABN 17 009 212 328) Phone: +61 3 8412 7000

Genetic Technologies Limited • Website : www.gtg.com.au • Email : info@gtg.com.au ABN 17 009 212 328 Registered Office • 60-66 Hanover Street Fitzroy VIC 3065 Australia • Postal Address P.O. Box 115 Fitzroy Victoria 3065 Australia Phone 61 3 9415 1135 • Fax 61 3 9417 2987